KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TAK) Cash & Equivalents (2018 - 2025)

Takeda Pharmaceutical (TAK) has 7 years of Cash & Equivalents data on record, last reported at $2.5 billion in Q1 2025.

  • For Q1 2025, Cash & Equivalents changed N/A year-over-year to $2.5 billion; the TTM value through Mar 2025 reached $2.5 billion, changed N/A, while the annual FY2025 figure was $2.5 billion, N/A changed from the prior year.
  • Cash & Equivalents reached $2.5 billion in Q1 2025 per TAK's latest filing, down from $4.0 billion in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $9.1 billion in Q1 2021 and bottomed at $2.5 billion in Q1 2025.
  • Average Cash & Equivalents over 4 years is $5.7 billion, with a median of $5.7 billion recorded in 2022.
  • Peak YoY movement for Cash & Equivalents: surged 55.88% in 2021, then crashed 44.83% in 2023.
  • A 4-year view of Cash & Equivalents shows it stood at $9.1 billion in 2021, then fell by 19.9% to $7.3 billion in 2022, then plummeted by 44.83% to $4.0 billion in 2023, then plummeted by 37.42% to $2.5 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $2.5 billion in Q1 2025, $4.0 billion in Q1 2023, and $7.3 billion in Q1 2022.